Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tilrekimig, tilrekimig
tilrekimig and rHuPH20 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| tilrekimig and rHuPH20 | EXPERIMENTAL | a single dose of co-mixed tilrekimig and rHuPH20 |
| Name | Type | Description |
|---|---|---|
| tilrekimig and rHuPH20 | DRUG | subcutaneous injection |
Inclusion Criteria: * BMI of 16-32 kg/m2; and a total body weight \>50 kg (110 lb). * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. Participants should be able to understand and sign...
Tilrekimig is an investigational small molecule being studied for the treatment of moderate-to-severe atopic dermatitis (eczema) and severe asthma. It is also being evaluated in healthy adults for pharmacokinetic studies. Tilrekimig is in Phase 3 clinical development and is not yet approved by regulatory authorities.
Tilrekimig is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting multiple clinical trials to evaluate the safety and efficacy of Tilrekimig in patients with atopic dermatitis and asthma.
Tilrekimig is currently in Phase 3 clinical development. Pfizer has initiated several Phase 3 trials for Tilrekimig in atopic dermatitis and asthma, as well as a Phase 1 pharmacokinetic study in healthy volunteers. Tilrekimig is investigational and has not received FDA approval.
Tilrekimig is being studied in several clinical trials. NCT07765888 and NCT07783425 are Phase 3 trials in moderate-to-severe atopic dermatitis. NCT07772921 is a Phase 3 trial in severe asthma. NCT07792941 is a Phase 1 study of single-dose pharmacokinetics in healthy adults when co-mixed with rHuPH20.
Tilrekimig is sometimes studied in combination with rHuPH20, but they are not the same drug. rHuPH20 is a recombinant human hyaluronidase that may be co-mixed with Tilrekimig in clinical trials to evaluate its pharmacokinetic profile. Tilrekimig itself is the investigational small molecule being developed by Pfizer.
The specific molecular target of Tilrekimig has not been disclosed in available clinical trial information. It is described as a small molecule being investigated for its therapeutic effects in atopic dermatitis and asthma. Further details about its mechanism of action are not publicly available at this time.